Table 1.
Demographics and disease characteristics for cladribine-treated patients with RRMS.
| Cohort demographics/time points | Baseline | 6 months* | 12 months* | 24 months* |
|---|---|---|---|---|
| Patients per time point, n (%) | 23 (100) | 16 (69.6) | 23 (100) | 13 (56.5) |
| Female patients, n (%) | 17 (73.9) | 11 (68.7) | 17 (73.9) | 10 (76.9) |
| Mean age, years, (± SD) | 39.3 (10.7) | 40.1 (9.9) | 40.3 (10.7) | 41.3 (10.9) |
| EDSS score, median (min, max) | 2 (0, 6.5) | 2 (0, 5.5) | 2 (0, 6) | 2 (0, 5.5) |
| Time since onset of MS, years, mean (± SD) | 8.6 (7.4) | – | – | – |
| Treatment-naïve patients, n (%) | 4 (17.4) | 4 (25) | 4 (17.4) | 2 (15.4) |
| Previous DMT, n (%) | 19 (82.6) | 12 (75) | 19 (82.6) | 11 (84.6) |
| Platform treatment | 8 (34.8) | 5 (31.3) | 8 (34.8) | 3 (23.1) |
| Highly active treatment | 11 (47.8) | 7 (43.8) | 11 (47.8) | 8 (61.5) |
Mean age relates to time point of taking of blood sample. Platform includes the following disease modifying therapies (DMT): teriflunomide, glatiramer acetate, dimethyl fumarate and interferon beta formulation. Highly active includes fingolimod, natalizumab and alemtuzumab.
*
Time after cladribine treatment onset.
DMT, disease modifying therapies; EDSS, expanded disability status scale; max, maximum; min, minimum; MS, multiple sclerosis; n, number; RRMS, relapsing-remitting MS; SD, standard deviation.